Welcome to our dedicated page for Innovent Biologi news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologi stock.
The news feed for INNOVENT BIOLGCS UNSP/ADR (IVBIY) aggregates company press releases and media updates from Innovent Biologics, Inc., a biopharmaceutical company focused on oncology, cardiovascular and metabolic, autoimmune and ophthalmology diseases. These announcements provide insight into clinical trial progress, regulatory milestones, product approvals and corporate strategy that can influence how investors and observers view IVBIY.
Recent news highlights include multiple updates on mazdutide, a dual GCG/GLP-1 receptor agonist licensed from Eli Lilly for development in China. Innovent has reported National Medical Products Administration approvals for mazdutide in chronic weight management for adults with overweight or obesity and for glycemic control in adults with type 2 diabetes, along with Phase 3 data from the GLORY and DREAMS clinical programs. Other cardiovascular and metabolic pipeline news covers tigulixostat, a xanthine oxidase inhibitor for gout, and IBI3032, an oral GLP-1 receptor agonist with U.S. FDA IND approval for Phase 1 trials.
Oncology news items describe the development of IBI363, a PD-1/IL-2α-bias fusion protein, including U.S. FDA clearance of an IND for a global Phase 3 trial in immunotherapy-resistant squamous non-small cell lung cancer and data presented at major oncology conferences. Additional coverage includes IBI343, an anti-CLDN18.2 ADC with Phase 1 results in gastric/gastroesophageal junction adenocarcinoma published in Nature Medicine and the launch of multi-regional Phase 3 studies.
Investors following IVBIY can use this page to review updates on Innovent’s broader pipeline, such as picankibart for psoriasis, IBI324 for retinal diseases, and other marketed products mentioned in interim results and R&D day communications. Bookmark this news section to monitor how clinical data releases, regulatory decisions and partnership announcements may shape the company’s long-term development and commercialization plans.
Innovent Biologics (HKEX: 01801) presented preclinical data for multiple novel cancer treatments at the AACR Annual Meeting 2025 in Chicago. The presentations showcased several groundbreaking developments including:
- IAR037: A novel CD40/PD-L1 bispecific antibody for treating advanced solid tumors resistant to immune checkpoint inhibitors
- IBI3010: A FRα targeting biparatopic antibody-drug conjugate showing superior results compared to existing treatments
- IBI3014: A TROP2xPD-L1 bi-specific ADC combining tumor killing with immune checkpoint blockade
- IBI3022: A bi-specific ADC targeting Trop2 and B7H4 for gynecologic cancers
- IBI3026: A first-in-class anti-PD-1/IL-12 fusion protein for immunotherapy-resistant tumors
- IBI3019: A novel tri-specific antibody targeting EGFR/CDH17/CD16A for colorectal cancer
These developments demonstrate Innovent's advancing global R&D capabilities and commitment to creating innovative cancer treatments.
Innovent Biologics (HKEX: 01801) announces NMPA approval of limertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. The approval is based on a Phase 3 trial of 337 patients comparing limertinib to gefitinib.
Key trial results show limertinib significantly improved median progression-free survival (PFS) to 20.7 months vs 9.7 months for gefitinib, representing a 56% risk reduction. In patients with CNS lesions, median CNS PFS was 20.7 months vs 7.1 months, showing a 72% risk reduction.
The drug demonstrated a well-tolerated safety profile with predominantly mild to moderate adverse events. This approval follows Innovent's commercial collaboration with ASK Pharm in 2024 for limertinib in Mainland China.
Innovent Biologics will present breakthrough clinical data at the 2025 ASCO Annual Meeting from May 30 to June 3 in Chicago. The company will showcase seven oral presentations, highlighting significant developments in their oncology pipeline.
Key presentations include data for IBI363 (PD-1/IL-2α-bias) in three indications: melanoma, colorectal cancer, and non-small cell lung cancer. Additionally, IBI343 (CLDN18.2 ADC) Phase 1b data in pancreatic cancer will receive an oral presentation, building on its previous success at ESMO Asia.
The presentations will also feature results from various clinical trials, including the ORIENT-21 Phase 3 study of sintilimab plus ICE in Hodgkin lymphoma, the SPRING-01 trial in rectal cancer, and the EP-STAR trial in nasopharyngeal carcinoma. Multiple poster presentations will showcase additional data from the company's diverse oncology portfolio.
Innovent Biologics (HKEX: 01801) has received Breakthrough Therapy Designation (BTD) from China's NMPA for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, for treating unresectable locally advanced or metastatic mucosal or acral melanoma in treatment-naive patients.
Clinical trials involving 26 patients with advanced acral or mucosal melanoma demonstrated remarkable results, with an overall objective response rate (ORR) of 61.5% and a disease control rate (DCR) of 84.6%. These outcomes significantly exceed current domestic immunotherapy standards.
The company has initiated a pivotal study comparing IBI363 monotherapy versus pembrolizumab (Keytruda®). Additionally, IBI363 has secured two Fast Track Designations from the U.S. FDA for treating squamous non-small cell lung cancer and melanoma.
Innovent Biologics (IVBIY) announces the presentation of preclinical data for multiple novel cancer therapeutics at the 2025 AACR Annual Meeting in Chicago from April 25-30. The presentations include data on several groundbreaking molecules:
- IAR037: A novel CD40/PD-L1 bispecific antibody for advanced solid tumors
- IBI3010: A FRα targeting biparatopic antibody-drug conjugate
- IBI3019: A first-in-class EGFR/CDH17/CD16A tri-specific antibody for colorectal cancer
- IBI3026: A novel anti-PD-1/IL-12 fusion protein
- IBI3014: A TROP2xPD-L1 bi-specific ADC
The company will also present findings on combination therapies involving olverembatinib with lisaftoclax for leukemia treatment. These presentations showcase Innovent's expanding technological capabilities in developing first-in-class bispecific antibodies, multi-specific antibodies, and ADCs for oncology applications.
Innovent Biologics announces historic 2024 results with its first-ever positive profit, reporting Non-IFRS profit of RMB331.6 million and EBITDA of RMB411.6 million. Total revenue reached RMB9,421.9 million, growing 51.8% year-over-year, with product sales revenue at RMB8,227.9 million (+43.6%).
The company expanded its portfolio to 15 approved products, including new launches in oncology and chronic diseases. Key products include Dovbleron® (ROS1 inhibitor), Limertinib (EGFR TKI), and Jaypirca® (BTK inhibitor). The company achieved an 84.9% gross profit margin and reduced S,G&A expenses ratio by 7.1 percentage points.
Innovent targets RMB20bn product revenue by 2027 and aims to advance five pipeline assets to global MRCT Phase 3 stage by 2030. The company maintains strong financial position with RMB10,221.1 million in cash and short-term assets.
Innovent Biologics (HKEX: 01801) has initiated dosing in a Phase 3 clinical trial (HeriCare-Ovarian01) of IBI354, a HER2 ADC, for platinum-resistant ovarian cancer (PROC). The study will compare IBI354 against standard chemotherapy, focusing on progression-free survival and overall survival as primary endpoints.
Previous Phase 1/2 results showed promising outcomes with IBI354:
- 40.2% overall objective response rate (ORR) and 81.6% disease control rate (DCR) across 87 PROC patients
- 52.5% ORR and 90.0% DCR in 40 patients treated with 12mg/kg dose
- 55.6% ORR and 88.9% DCR in HER2 IHC 1+ subjects at 12mg/kg
The drug demonstrated a favorable safety profile with 21.5% grade 3+ treatment-related adverse events, low discontinuation rates (1.6%), and no treatment-related deaths. Common side effects included nausea, decreased white blood cell count, and anemia.
Innovent Biologics (IVBIY) and HUTCHMED have announced positive results from their FRUSICA-2 Phase 2/3 clinical trial, evaluating sintilimab combined with fruquintinib as second-line treatment for advanced renal cell carcinoma (RCC) in China.
The study met its primary endpoint of progression-free survival (PFS) and showed improvements in secondary endpoints, including objective response rate (ORR) and duration of response (DoR). The trial compared the combination therapy against axitinib or everolimus monotherapy for second-line RCC treatment.
The combination has previously received conditional approval from China's NMPA for treating advanced endometrial cancer with pMMR tumors based on the FRUSICA-1 study. The companies plan to proceed with NDA filings in the coming months, aiming to make this treatment option available to patients who have progressed on previous therapy.
Innovent Biologics has received NMPA approval for SYCUME® (teprotumumab N01), China's first and world's second IGF-1R antibody drug for treating thyroid eye disease (TED). This breakthrough ends a 70-year period without new TED treatments in China.
TED, an autoimmune disorder affecting orbital health, has an annual incidence of 16 per 100,000 in women and 2.9 per 100,000 in men. The Phase 3 RESTORE-1 study demonstrated that 85.8% of patients achieved ≥2 mm proptosis reduction at Week 24 with SYCUME® treatment.
SYCUME® offers advantages including a liquid injection formation, improved stability, and better patient compliance. This approval provides a more accessible treatment option compared to the existing IGF-1R antibody treatment available overseas, which costs approximately 3 million RMB per course.
Innovent Biologics (IVBIY) has initiated a pivotal study of IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, comparing it head-to-head with pembrolizumab in melanoma patients. The first patient has been dosed in this registrational trial for treating unresectable locally advanced or metastatic mucosal or acral melanoma in treatment-naive patients.
Early clinical trials of IBI363 showed promising results:
- 61.5% overall objective response rate (ORR)
- 84.6% disease control rate (DCR)
- Sustained tumor responses and long-term benefits observed
The safety profile has been manageable, with common treatment-related adverse events including arthralgia, anemia, thyroid dysfunction, and rash. The study's primary endpoint is progression-free survival (PFS), assessed by an Independent Radiology Review Committee using RECIST v1.1 criteria.